GlassScriptPhysician profile
Marlon G Ramilo
NPI 1659316412
$496,297.83
in general payments reported to CMS, 2019-2025
37 companies · $87K in 2025
The $87K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54K · 2020: $11K · 2021: $8,902 · 2022: $104K · 2023: $158K · 2024: $73K · 2025: $87K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $255K · Travel and Lodging: $46K · Food and Beverage: $17K · Consulting Fee: $350 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $255,253.31 |
| Travel and Lodging | $45,851.07 |
| Food and Beverage | $17,042.58 |
| Consulting Fee | $350.00 |
| Education | $177.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $207,652.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $148,515.50 | 2022-2025 | Verquvo, Winrevair, Capvaxive |
| Janssen Pharmaceuticals, INC | $91,124.92 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $17,145.53 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $8,590.43 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $7,597.58 | 2019-2025 | Lifevest |
| Abbott Laboratories | $5,010.54 | 2019-2025 | Gallant, Jot Dx, Aveir |
| E.R. Squibb & Sons, L.L.C. | $1,707.23 | 2019-2025 | Camzyos, Eliquis |
| Abiomed | $1,096.00 | 2019-2025 | Impella |
| Amgen INC. | $991.71 | 2019-2025 | Repatha, Repatha |
| United Therapeutics Corporation | $980.30 | 2020-2025 | Tyvaso, Orenitram, Tyvaso |
| Astrazeneca Pharmaceuticals LP | $655.29 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $546.18 | 2019-2024 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $484.21 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Akcea Therapeutics, INC. | $471.11 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $394.30 | 2025 | Biomonitor, Amvia Edge, Pamira |
| Lilly USA, LLC | $334.70 | 2019-2023 | Mounjaro |
| Esperion Therapeutics, INC. | $330.62 | 2020-2021 | |
| Boston Scientific Corporation | $321.27 | 2019-2024 | Avvigo Guidance System, Accolade Sr |
| Vifor Pharma, INC. | $299.21 | 2019-2021 | |
| Shockwave Medical, INC | $259.53 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Sanofi-Aventis U.S. LLC | $244.38 | 2019 | |
| Medtronic Vascular, INC. | $233.15 | 2019-2020 | |
| Medtronic, INC. | $215.28 | 2021-2022 | |
| Sobi, INC | $150.00 | 2023 | |
| Atricure, INC. | $136.99 | 2025 | Synergy Ablation System, Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Regeneron Healthcare Solutions, INC. | $132.11 | 2019-2020 | |
| Mylan Specialty L.P. | $126.78 | 2019-2023 | Yupelri |
| Cardiovascular Systems INC. | $123.78 | 2021-2022 | |
| Scpharmaceuticals INC. | $122.31 | 2023-2024 | |
| Astellas Pharma US INC | $91.84 | 2019 | |
| Pfizer INC. | $65.78 | 2020-2021 | |
| Edwards Lifesciences Corporation | $60.00 | 2020-2022 | |
| Gilead Sciences, INC. | $48.07 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $15.26 | 2023 | Inpefa |
| Amarin Pharma, INC. | $13.74 | 2020 | |
| Bardy Diagnostics, INC. | $9.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlon Ramilo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.